SecBot SecBot
PRESS-RELEASE ·Filed May 13, 2026

TARA

Protara Therapeutics
NEUTRAL
Impact 4/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor upcoming data presentations at AUA (May 15) and ISSVA (May 20) for TARA-002 in NMIBC and LMs, as positive results could drive near-term upside. Additionally, THRIVE-3 interim results in 2H 2026 represent a key catalyst for IV Choline Chloride.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$5.20
T+0 close · May 13, 2026 · via day close
Latest settled
−20.77%
T+60 · $4.12
Vs SPY
−25.21%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 13 $5.20entry
  2. T+1 · 6mo ago +1.92%α +1.15% · $5.30
  3. T+5 · 6mo ago −16.54%α −15.38% · $4.34
  4. T+20 · 5mo ago −29.81%α −29.19% · $3.65
  5. T+60 · 3mo ago −20.77%α −25.21% · $4.12
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Protara Therapeutics reported Q1 2026 net loss of $0.31 per share, beating consensus estimates of $0.37 loss, with cash of $177.4M to fund operations into 2028. Pipeline progress includes planned BLA submission for TARA-002 in lymphatic malformations in 2H 2027 and multiple data presentations in May 2026.

Key Financial Metrics

EPS
−$0.31
est −$0.37 · +16.2%
Rating
beat

Key Facts

  • Q1 2026 net loss $17.8M ($0.31/share) vs consensus $0.37 loss per share
  • Cash, equivalents and marketable securities $177.4M as of March 31, 2026
  • Plan to submit BLA for TARA-002 in LMs in 2H 2027
  • Enrollment completion for BCG-Unresponsive cohort in ADVANCED-2 trial expected 2H 2026
  • Interim results for THRIVE-3 (IV Choline Chloride) expected 2H 2026
  • Research and development expenses increased to $13.6M from $9.1M in prior year period

Financial Impact

Net loss per share improved 16.2% versus consensus; cash burn rate increased with R&D expenses up 48% YoY

net losscash positionR&D expenses

Risk Factors

  • Clinical trial enrollment delays or negative data readouts
  • Cash burn rate may require future capital raises before BLA submission
  • Regulatory setbacks for TARA-002 BLA or THRIVE-3

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3293938

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 13, 2026